Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Tarceva in EGFR-mutant Advanced Lung Adenocarcinoma
NCT02704767Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Jun 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in lung adenocarcinoma comparing Tarceva + Placebo with Tarceva + Apatinib (2 arms). Primary endpoint: Progression Free Survival at 36 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02704767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704767.